You are Here : BDR Pharma lines up more compulsory licences: Sources

Friday, 06:25

Indian generic drug maker BDR Pharma's plans could draw new battles lines over intellectual property rights. After seeking a compulsory license for leukemia drug Sprycel, BDR Pharma is setting its sight on more patent-protected anti-cancer drugs, reports CNBC-TV18's Archana Shukla.
MAY 27, 2017
08:01 AM

cnbc tv18 shows

All Shows

mytv on mobile

Track your portfolio on the go with

moneycontrol app

Follow us on
Available On